Fujirebio Europe enters an agreement with ADx NeuroSciences for the commercialization of novel biomarkers

Company news

Fujirebio Europe and ADx NeuroSciences announced today that they have concluded an agreement related to the development and commercialization of new assays in the field of neurodegeneration.

Included in the scope of the agreement is the supply of antibodies as well as the transfer of know-how and/or prototype assays from ADx to Fujirebio for the commercialization of Alzheimer’s Disease assays targeting amyloid beta that use blood samples instead of cerebrospinal fluid (CSF) and novel CSF assays for neurology biomarkers NPTX2 and sTREM2.

Fujirebio manufactures neurodegeneration assays in ELISA format as well as in chemiluminescence format for use on Lumipulse® automated analyzers. According to Christiaan De Wilde, CEO of Fujirebio Europe, ”Our collaboration with ADx is entirely aligned with our mission to position Fujirebio Europe as the worldwide Centre of Excellence for neurology within the Fujirebio group of companies. We see this as the first of several initiatives that will expand the range of diagnostic tools that we can make available to clinicians and researchers in the field of neurodegeneration.”

ADx NeuroSciences is an R&D driven company specialized in the development of novel neurodegeneration biomarkers for pharma and diagnostic companies. Koen Dewaele, CEO of ADx NeuroSciences stated, “Our agreement with Fujirebio underlines our preference to work with those that are committed to invest and grow in the field of neurodegeneration. We see it as an important step in the further growth of ADx NeuroSciences as an independent R&D company supporting both pharmaceutical and in vitro diagnostics (IVD) companies in their diagnostic biomarker development and use.”


About Fujirebio

Fujirebio is a global leader in the field of high-quality IVD testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.

Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network.

Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.

Fujirebio is a wholly-owned subsidiary of H.U. Group Holdings Inc. (formerly known as Miraca Holdings Inc. and listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1.200 people in Asia, Europe and America.


About ADx NeuroSciences

ADx NeuroSciences is an R&D driven company specialized in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production and worldwide commercialization of novel biomarkers.

ADx NeuroSciences, Gent Belgium, was founded in 2011 and is now working with the top pharmaceutical and diagnostic companies in US, Europe, Japan and China. These collaborations result in new diagnostic assays that support the development of promising drugs either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays are used in neurodegenerative diseases like Alzheimer’s and Parkinson’s and can be applied to a variety of platforms for research up to IVD use.

ADx NeuroSciences is a growing privately held company and employs today 18 highly educated and motivated people.